EMA Authorised: mResvia (Respiratory syncytial virus mRNA vaccine (nucleoside modified)) — Moderna Biotech Spain, S.L.

View source ↗

Summary

The EMA has authorised mResvia, a nucleoside-modified RSV mRNA vaccine by Moderna Biotech Spain, S.L., for prevention of respiratory syncytial virus infections.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infections

Drugs mentioned

• mResvia (Respiratory syncytial virus mRNA vaccine (nucleoside modified))

Snippet

Status: Authorised. Therapeutic area: Respiratory Syncytial Virus Infections. MAH: Moderna Biotech Spain, S.L.. Decision date: 02/10/2025